KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to -$641,000.

  • Aurinia Pharmaceuticals' Change in Accured Expenses fell 91.92% to -$641,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$308,000, marking a year-over-year increase of 91.89%. This contributed to the annual value of $13.3 million for FY2024, which is 9.68% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Change in Accured Expenses of -$641,000 as of Q3 2025, which was down 110.22% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Change in Accured Expenses peaked at $17.5 million during Q4 2024, and registered a low of -$23.4 million during Q1 2025.
  • In the last 3 years, Aurinia Pharmaceuticals' Change in Accured Expenses had a median value of $342,000 in 2023 and averaged $700,636.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Change in Accured Expenses slumped by 675.61% in 2021, and later surged by 5,931.36% in 2022.
  • Aurinia Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $2.9 million in 2021, then plummeted by 78.95% to $616,000 in 2022, then tumbled by 44.48% to $342,000 in 2023, then spiked by 5,007.89% to $17.5 million in 2024, then slumped by 91.92% to -$641,000 in 2025.
  • Its Change in Accured Expenses was -$641,000 in Q3 2025, compared to $6.3 million in Q2 2025 and -$23.4 million in Q1 2025.